Genprex (GNPX) Net Cash Flow (2016 - 2026)
Genprex (GNPX) posted quarterly Net Cash Flow of $10.2 million for Q1 2026, up 447.41% year-over-year from $1.9 million in Q1 2025, and up 51.89% quarter-over-quarter from $6.7 million in Q4 2025.
Genprex (GNPX) Net Cash Flow (2016 - 2026) Analysis & Trends
Genprex's Net Cash Flow history runs 11 years deep, the most recent figure standing at $10.2 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 447.41% year-over-year to $10.2 million; the TTM figure through Mar 2026 stood at $14.6 million (up 407.05% YoY), while the FY2025 annual figure was $6.2 million, up 221.29% from the prior year.
- Net Cash Flow for Q1 2026 stood at $10.2 million, up from $6.7 million in the prior quarter.
- The five-year high for Net Cash Flow was $10.2 million in Q1 2026, with the low at -$8.1 million in Q2 2023.
- The 5-year median for Net Cash Flow is -$2.1 million (2025), against an average of -$1.2 million.
- The sharpest annual moves came in 2024 and 2025: Net Cash Flow plunged 155.29% in 2024, then soared 5833.67% in 2025.
- Genprex's Net Cash Flow stood at -$4.6 million in 2022, then slipped by 9.02% to -$5.0 million in 2023, then soared by 102.28% to $113379.0 in 2024, then jumped by 5833.67% to $6.7 million in 2025, then jumped by 51.89% to $10.2 million in 2026.
- Business Quant data shows GNPX's Net Cash Flow at $10.2 million in Q1 2026, $6.7 million in Q4 2025, and -$243529.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Genprex | 1.88 Mn | -13.28 Mn | - | -2.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.22 Mn |
| Mar 31, 2026 | 10.22 Mn |
| Dec 31, 2025 | 6.73 Mn |
| Dec 31, 2025 | 6.73 Mn |
| Sep 30, 2025 | -243,529.00 |
| Sep 30, 2025 | -243,529.00 |
| Jun 30, 2025 | -2.12 Mn |
| Jun 30, 2025 | -2.12 Mn |
| Mar 31, 2025 | 1.87 Mn |
| Mar 31, 2025 | 1.87 Mn |
| Dec 31, 2024 | 113,379.00 |
| Dec 31, 2024 | 113,379.00 |
| Sep 30, 2024 | -970,743.00 |
| Sep 30, 2024 | -970,743.00 |
| Jun 30, 2024 | -5.76 Mn |
| Jun 30, 2024 | -5.76 Mn |
| Mar 31, 2024 | 1.48 Mn |
| Mar 31, 2024 | 1.48 Mn |
| Dec 31, 2023 | -4.97 Mn |
| Dec 31, 2023 | -4.97 Mn |